Amarin | AMRN - Current Assets

Stock Price
14.56
Daily Change
-0.22 -1.49%
Monthly
-1.09%
Yearly
37.62%
Q2 Forecast
14.12

Amarin reported $626.02M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
AbbVie USD 33.53B 4.47B Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Amarin USD 626.02M 23.87M Mar/2026
AstraZeneca USD 29.61B 890M Mar/2026
BioCryst Pharmaceuticals USD 373.62M 30.72M Mar/2026
DBV Technologies USD 212.94M 124.06M Dec/2025
Esperion Therapeutics USD 459.46M 3.11M Mar/2026
GlaxoSmithKline GBP 17.76B 251M Mar/2026
Halozyme Therapeutics USD 1B 177.83M Mar/2026
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
Novartis USD 26.61B 3.85B Mar/2026